Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR.
NIDAT32 Addiction Research Training Program, Psychiatric Research Institute, University of Arkansas for Medical Sciences College of Medicine, Little Rock, AR.
Health Serv Res. 2018 Oct;53(5):3329-3349. doi: 10.1111/1475-6773.12836. Epub 2018 Feb 25.
Evaluate the association between opioid therapy and health-related quality of life (HRQoL) in participants with chronic, noncancer pain (CNCP).
Medical Expenditure Panel Survey Longitudinal, Medical Conditions, and Prescription Files.
Using a retrospective cohort study design, the Mental Health Component (MCS12) and Physical Health Component (PCS12) scores of the Short Form-12 Version 2 were assessed to measure mental and physical HRQoL.
Chronic, noncancer pain participants were classified as chronic, nonchronic, and nonopioid users. One-to-one propensity score matching was employed to match chronic opioid users to nonchronic opioid users plus nonchronic opioid users and chronic opioid users to nonopioid users.
A total of 5,876 participants were identified. After matching, PCS12 was not significantly different between nonchronic versus nonopioid users (LSM Diff = -0.98, 95% CI: -2.07, 0.10), chronic versus nonopioid users (LSM Diff = -2.24, 95% CI: -4.58, 0.10), or chronic versus nonchronic opioid users (LSM Diff = -2.23, 95% CI: -4.53, 0.05). Similarly, MCS12 was not significantly different between nonchronic versus nonopioid users (LSM Diff = 0.76, 95% CI: -0.46, 1.98), chronic versus nonopioid users (LSM Diff = 1.08, 95% CI: -1.26, 3.42), or chronic versus nonchronic opioid users (LSM Diff = -0.57, 95% CI: -2.90, 1.77).
Clinicians should evaluate opioid use in participants with CNCP as opioid use is not correlated with better HRQoL.
评估慢性非癌症疼痛（CNCP）患者阿片类药物治疗与健康相关生活质量（HRQoL）之间的关联。
医疗支出面板调查纵向、医疗状况和处方档案。
采用回顾性队列研究设计，使用 12 项简短健康调查量表精神健康分量表（MCS12）和身体健康分量表（PCS12）评估来衡量精神和身体 HRQoL。
将慢性非癌症疼痛参与者分为慢性非阿片类使用者、慢性阿片类使用者和非阿片类使用者。采用 1:1 倾向评分匹配将慢性阿片类使用者与慢性非阿片类使用者加非阿片类使用者进行匹配，将慢性阿片类使用者与非阿片类使用者进行匹配。
共确定了 5876 名参与者。匹配后，非慢性组与非阿片类使用者相比，PCS12 无显著差异（LSM 差值=-0.98，95%CI：-2.07，0.10），慢性组与非阿片类使用者相比（LSM 差值=-2.24，95%CI：-4.58，0.10），或慢性组与慢性非阿片类使用者相比（LSM 差值=-2.23，95%CI：-4.53，0.05）。同样，非慢性组与非阿片类使用者相比，MCS12 无显著差异（LSM 差值=0.76，95%CI：-0.46，1.98），慢性组与非阿片类使用者相比（LSM 差值=1.08，95%CI：-1.26，3.42），或慢性组与慢性非阿片类使用者相比（LSM 差值=-0.57，95%CI：-2.90，1.77）。
临床医生在评估 CNCP 患者的阿片类药物使用情况时，应考虑到阿片类药物的使用与更好的 HRQoL 无关。
